Golly increases investment in tumor lipid metabolism and oral checkpoint inhibitor R&D

On March 30, Gerry Pharmaceuticals announced that it would increase R&D investment in tumor lipid metabolism and oral checkpoint inhibitors.

Note: 1.

The data shows that the overall response rate (ORR) of ASC40+bevacizumab is 65%, including 20% ​​complete response (CR) and 45% partial response (PR).

At present, the company plans to launch a randomized, double-blind, placebo-controlled pivotal phase II clinical trial of ASC40 (TVB-2640) combined with bevacizumab in China.

It has been reported that lipid metabolism plays a key role in a variety of tumors.

In addition to the use of fatty acid synthase inhibitors in combination with anti-angiogenic drugs, the company's internal data and external research papers show that fatty acid synthase inhibitors combined with signal transduction inhibitors and immunotherapy have the potential to treat a variety of tumors.

Use ASC40 combined with chemotherapy to treat high-grade astrocytoma immediately after surgery and radiotherapy;

ASC40 is combined with other therapies to treat a variety of solid tumors.

In addition to tumor lipid metabolism candidate drugs that target fatty acid synthase, the company's self-developed oral PD-L1 small molecule inhibitor has a potential for anti-tumor activity in animal models than a marketed anti-PD-L1 antibody Advantage.